IQV Stock Analysis — IQVIA Holdings Inc.
Sector: Healthcare Services
AI Verdict
IQVIA trades at 13.2x next year's earnings with 58.6% EPS growth expected—this is cheap for the growth on offer given its data-driven moat, but any stumble in execution could close that valuation gap fast.
Competitive Moat
IQVIA provides clinical research, real-world evidence, and data analytics services to pharmaceutical and biotech companies, leveraging one of the largest proprietary healthcare datasets globally. Its moat comes from deep integration into pharma R&D workflows and exclusive access to longitudinal patient data, making it hard for new entrants to replicate its scale or data depth.
Summary
IQVIA trades at just 13.2x next year's earnings while analysts expect a huge 58.6% jump in EPS, making it a standout for value-driven growth.
Where It Stands
IQVIA is up 18.41% over the past year with an RSI of 63.3 (neutral to elevated), and its 13.2x forward P/E is well below the healthcare sector median of 22x.
Key Metrics
- RSI: 63.3 — Near Overbought
- Trailing P/E: 20.9x
- Forward P/E: 13.2x
- PEG Ratio: 0.36
- Earnings Growth: +0.6%
- Revenue Growth: +0.1%
- Market Cap: $28.2B
- 1-Year Return: 18.41%
- 52-Week High: $247.05
- 52-Week Low: $134.65
Analyst Consensus
27 Buy · 4 Hold · 0 Sell (31 analysts)
Bull Case
With forward EPS growth projected at 58.6% and a trailing PEG ratio of 0.36, IQVIA offers growth at a price that looks cheap by any historical standard.
Bear Case
If the forward P/E reverts even halfway to the sector median (from 13.2x to 18x), shares could see a 36% multiple expansion risk if growth disappoints.
Catalyst to Watch
Watch for upcoming clinical trial wins or new data partnerships, as either could validate the aggressive earnings growth forecast.